pubmed.ncbi.nlm.nih.gov

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia - PubMed

Randomized Controlled Trial

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia

Enrique Alvarez et al. J Clin Psychopharmacol. 2006 Jun.

Abstract

Objective: To evaluate the efficacy of olanzapine compared with risperidone in negative symptoms, after 1 year of treatment, in schizophrenic outpatients with prominent negative symptoms.

Methods: This was a multicenter, randomized, monitored, open-label, parallel, dose-flexible, 1-year study of outpatients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) with prominent negative symptoms (Scale for the Assessment of Negative Symptoms [SANS] summary score > or =10) previously treated with conventional antipsychotics. Patients were randomly assigned to treatment with an initial dose of olanzapine 10 mg/d or more (n = 120) or risperidone 3 mg/d or more (n = 115). The primary efficacy measure was the SANS summary score. Secondary efficacy measures included Scale for the Assessment of Positive Symptoms, Clinical Global Impression of Severity Scale, Calgary Depression Scale, and Social Functioning Scale. The response rate was defined as 30% or more of improvement in the SANS summary score.

Results: The mean dose throughout the study was 12.2 mg/d (+/-5.8 mg/d) for olanzapine and 4.9 mg/d (+/-2.0 mg/d) for risperidone. At 1 year, olanzapine patients showed significantly higher improvement than risperidone patients on the SANS summary (P = 0.015) and on the affective flattening (P = 0.007) and avolition/apathy (P = 0.028) SANS subscales. There were also significant improvements in favor of olanzapine in the Scale for the Assessment of Positive Symptoms summary (P = 0.021), Clinical Global Impression of Severity (P = 0.008), and Social Functioning Scale total (P < 0.001) scores. The response rate was greater (P = 0.001) in the olanzapine cohort (69.2%) than in the risperidone cohort (48.7%). Olanzapine patients reported less extrapyramidal side effects but a higher incidence of clinically important body weight increase than risperidone patients.

Conclusions: Long-term treatment with olanzapine was associated with significantly better improvement in negative symptoms as compared with risperidone-treated schizophrenic outpatients with prominent negative symptoms.

PubMed Disclaimer

Cited by

Olanzapine versus other atypical antipsychotics for schizophrenia.
Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S. Komossa K, et al. Cochrane Database Syst Rev. 2010 Mar 17;2010(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Cochrane Database Syst Rev. 2010. PMID: 20238348 Free PMC article. Review.
Risperidone versus other atypical antipsychotics for schizophrenia.
Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S. Komossa K, et al. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2. Cochrane Database Syst Rev. 2011. PMID: 21249678 Free PMC article. Review.
Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.
Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Kishimoto T, et al. World Psychiatry. 2019 Jun;18(2):208-224. doi: 10.1002/wps.20632. World Psychiatry. 2019. PMID: 31059621 Free PMC article.
Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study.
Kumar S, Chaudhury S. Kumar S, et al. Ind Psychiatry J. 2014 Jan;23(1):27-35. doi: 10.4103/0972-6748.144953. Ind Psychiatry J. 2014. PMID: 25535442 Free PMC article.
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H, Zhornitsky S, Brunelle S, Stip E. Moteshafi H, et al. Drug Saf. 2012 Oct 1;35(10):819-36. doi: 10.1007/BF03261978. Drug Saf. 2012. PMID: 22967188

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia - PubMed